Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Cidara Therapeutics Inc (NASDAQ: CDTX) closed at $24.88 in the last session, down -7.85% from day before closing price of $27.00. In other words, the price has decreased by -$7.85 from its previous closing price. On the day, 0.23 million shares were traded. CDTX stock price reached its highest trading level at $27.6 during the session, while it also had its lowest trading level at $21.5.
Ratios:
We take a closer look at CDTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.54 and its Current Ratio is at 3.54. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on December 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $34.
On November 08, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $33.
H.C. Wainwright Upgraded its Neutral to Buy on August 14, 2024, while the target price for the stock was maintained at $24.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 11 ’24 when Sandison Taylor sold 924 shares for $11.64 per share. The transaction valued at 10,752 led to the insider holds 23,067 shares of the business.
Tari Leslie sold 909 shares of CDTX for $10,580 on Sep 11 ’24. The CHIEF SCIENTIFIC OFFICER now owns 17,788 shares after completing the transaction at $11.64 per share. On Jun 07 ’24, another insider, Stein Jeffrey, who serves as the President & CEO of the company, bought 8,000 shares for $13.21 each. As a result, the insider paid 105,680 and bolstered with 24,580 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDTX now has a Market Capitalization of 272316576 and an Enterprise Value of -67797664. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.33 while its Price-to-Book (P/B) ratio in mrq is 1.52. Its current Enterprise Value per Revenue stands at -1.259 whereas that against EBITDA is 2.252.
Stock Price History:
Over the past 52 weeks, CDTX has reached a high of $28.42, while it has fallen to a 52-week low of $10.00. The 50-Day Moving Average of the stock is 28.96%, while the 200-Day Moving Average is calculated to be 73.50%.
Shares Statistics:
According to the various share statistics, CDTX traded on average about 62.18K shares per day over the past 3-months and 140570 shares per day over the past 10 days. A total of 7.05M shares are outstanding, with a floating share count of 4.66M. Insiders hold about 57.40% of the company’s shares, while institutions hold 27.79% stake in the company. Shares short for CDTX as of 1728950400 were 66976 with a Short Ratio of 0.58, compared to 1726185600 on 65137. Therefore, it implies a Short% of Shares Outstanding of 66976 and a Short% of Float of 1.05.
Earnings Estimates
At present, 4.0 analysts are actively evaluating the performance of Cidara Therapeutics Inc (CDTX) in the stock market.The consensus estimate for the next quarter is -$4.26, with high estimates of -$3.38 and low estimates of -$5.13.
Analysts are recommending an EPS of between -$18.89 and -$27.35 for the fiscal current year, implying an average EPS of -$22.43. EPS for the following year is -$8.57, with 4.0 analysts recommending between -$4.77 and -$14.39.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for CDTX’s current fiscal year. The highest revenue estimate was $10M, while the lowest revenue estimate was $1.27M, resulting in an average revenue estimate of $6.03M. In the same quarter a year ago, actual revenue was $63.91M
